Compare Walt Disney Co (DIS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs Mesoblast Limited — how do they compare? Walt Disney Co trades at $103.23 (market cap $178.16B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Walt Disney Co is far larger — about 82.5× Mesoblast Limited's market cap, and Walt Disney Co pays a 1.45% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| DIS | MESO | |
|---|---|---|
Market Cap | $178.16B | $2.16B |
Volume | 7,546,013 | — |
Sector | Media | Technology |
52-Week High | $118.86 | $20.96 |
52-Week Low | $92.40 | $12.88 |
Enterprise Value | $219.02B | $2.17B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $103.51, down 1.32% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with four consecutive quarterly earnings beats, revenue growth to $94.43B in 2025, and improving profit margins. Recent news highlights advertising opportunities from major events and ongoing FCC regulatory challenges.
Outlook remains positive with analyst consensus target of $126 representing 22% upside potential. Key opportunities include streaming growth and theme park investments, while risks involve regulatory disputes and box office performance variability. Wall Street maintains strong buy sentiment with 62.5% of analysts recommending purchase.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
